PharMerica Co. (PMC) Position Trimmed by Citadel Advisors LLC
Citadel Advisors LLC cut its holdings in shares of PharMerica Co. (NYSE:PMC) by 95.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 11,357 shares of the company’s stock after selling 250,780 shares during the quarter. Citadel Advisors LLC’s holdings in PharMerica were worth $333,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Shell Asset Management Co. purchased a new position in PharMerica during the third quarter worth about $1,946,000. California Public Employees Retirement System raised its holdings in shares of PharMerica by 13.8% in the 2nd quarter. California Public Employees Retirement System now owns 92,400 shares of the company’s stock worth $2,426,000 after purchasing an additional 11,200 shares during the period. Chicago Equity Partners LLC purchased a new position in shares of PharMerica in the 2nd quarter worth about $2,061,000. Victory Capital Management Inc. raised its holdings in shares of PharMerica by 40.1% in the 2nd quarter. Victory Capital Management Inc. now owns 1,294,142 shares of the company’s stock worth $33,971,000 after purchasing an additional 370,266 shares during the period. Finally, Northern Trust Corp raised its holdings in shares of PharMerica by 12.8% in the 2nd quarter. Northern Trust Corp now owns 440,400 shares of the company’s stock worth $11,561,000 after purchasing an additional 50,039 shares during the period. Hedge funds and other institutional investors own 89.97% of the company’s stock.
PharMerica Co. (PMC) traded up $0.05 during trading on Thursday, hitting $29.25. The stock had a trading volume of 1,371,600 shares, compared to its average volume of 283,015. The stock has a market cap of $910.27, a P/E ratio of 15.15, a price-to-earnings-growth ratio of 1.27 and a beta of 0.82. The company has a current ratio of 2.58, a quick ratio of 1.79 and a debt-to-equity ratio of 0.79. PharMerica Co. has a 52 week low of $22.00 and a 52 week high of $29.50.
PharMerica (NYSE:PMC) last posted its earnings results on Thursday, November 9th. The company reported $0.46 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.49 by ($0.03). PharMerica had a net margin of 0.83% and a return on equity of 10.94%. The company had revenue of $595.10 million during the quarter, compared to analyst estimates of $596.80 million. analysts expect that PharMerica Co. will post 1.92 EPS for the current fiscal year.
In other news, CEO Gregory S. Weishar sold 521,089 shares of the stock in a transaction dated Thursday, December 7th. The stock was sold at an average price of $29.25, for a total value of $15,241,853.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In the last quarter, insiders sold 534,089 shares of company stock valued at $15,243,073. Insiders own 5.04% of the company’s stock.
PMC has been the topic of a number of research reports. Zacks Investment Research downgraded PharMerica from a “buy” rating to a “hold” rating in a report on Wednesday, October 4th. ValuEngine upgraded PharMerica from a “hold” rating to a “buy” rating in a report on Tuesday, October 31st. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $30.50.
ILLEGAL ACTIVITY WARNING: This news story was originally published by Daily Political and is owned by of Daily Political. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://www.dailypolitical.com/2017/12/14/pharmerica-co-pmc-position-trimmed-by-citadel-advisors-llc.html.
Receive News & Ratings for PharMerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharMerica and related companies with MarketBeat.com's FREE daily email newsletter.